I am a BRC and James Martin School funded Post Doctoral Researcher in the OVG lab, mainly working on B cell studies based around the clinical trials. Prior to working in OVG I completed and MSc in Immunology at Kings College London, followed by an 18 month post as a Guest Researcher in the Respiratory Diseases Branch at CDC in Atlanta. I completed my PhD with Andy at OVG, finishing in 2008. My main focus now is on B cell responses to vaccine antigens and I have developed assays to identify antigen specific B cells by ELISpot and Flow Cytometry. This work has been applied to studies both in the UK and in Fiji where the data are being used to help optimise pneumococcal vaccine schedules.
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Ramasamy MN. et al, (2021), Lancet, 396, 1979 - 1993
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
Flaxman A. et al, (2021), Lancet, 398, 981 - 990
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial.
Frater J. et al, (2021), Lancet HIV, 8, e474 - e485
Divergent trajectories of antiviral memory after SARS-Cov-2 infection
Tomic* A. et al, (2021)
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
Barrett JR. et al, (2021), Nat Med, 27